NCT01471106 2024-07-10
Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
Clinical Trials
11 trialsNCT01306942 2023-03-30
Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients
Spanish Breast Cancer Research Group
Phase 1/2 Completed
NCT00566618 2022-02-25
Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00820170 2019-08-13
Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00410813 2017-07-02
S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone
SWOG Cancer Research Network
Phase 2 Completed
NCT00754325 2016-05-26
Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor
Bristol-Myers Squibb
Phase 2 Completed
NCT00452673 2015-03-24
Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer
Bristol-Myers Squibb
Phase 1 Completed
NCT00924352 2014-10-13
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Accelerated Community Oncology Research Network
Phase 1/2 Completed
NCT00546104 2013-07-17
Phase II Dasatinib Study in Advanced Breast Cancer
Duke University
Phase 2 Completed
NCT00767520 2013-02-28
Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT00371345 2011-04-26
Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer
Bristol-Myers Squibb
Phase 2 Completed